Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04084717

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:26:22.997333+00:00

Published At

2024-07-16T00:00:00+00:00

Record Updated At

2024-07-16

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-squamous Non-small-cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "ROS1 Gene Rearrangement", "MET Activating Mutation", "MET Amplification"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-07-16"

protocolSection.identificationModule.nctId

"NCT04084717"

protocolSection.identificationModule.officialTitle

"Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-squamous Non-small-cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Stage IV Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• ROS1 Gene Rearrangement (protocolSection.conditionsModule.conditions)
• MET Activating Mutation (protocolSection.conditionsModule.conditions)
• MET Amplification (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.